Background: Genital granulomatosis [GG] is a metastatic form of Crohn's disease [CD], characterised by granulomatous inflammation of the genital skin without contact with the gastrointestinal tract. Little is known about GG, as most publications are case reports or small series, and only sporadic in male cases. Methods and Aims: Cases of GG were retrospectively collected through the Collaborative Network For Exceptionally Rare case reports project of the European Crohn´s and Colitis Organisation. Results: A total of 43 patients [9 males, 34 females] were diagnosed as having GG, mostly as oedema and/or ulcers. Histological confirmation of granulomas was obtained in 70% of the cases. CD location was colonic or ileocolonic in 97% and perianal disease was documented in 57%. There was no significant difference between males and females in CD phenotype or genital lesions. GG was the first manifestation of inflammatory bowel disease [IBD] in one-third of the patients; these patients were younger at the time of GG occurrence and they all were non-smokers. GG occurred in the absence of gastrointestinal disease activity in 30% of the cases. Ten out of 11 patients [91%] responded to systemic corticosteroid treatment, 5/9 patients responded to immunomodulators, and 9/11 patients responded to anti-tumour necrosis factor alpha [TNF-α] agents. Conclusions: GG is a rare extraintestinal manifestation of CD. It mainly occurs among women, in the setting of colonic involvement of CD, and perianal disease is often associated. Most cases are successfully managed with systemic corticosteroids or anti-TNF agents.
Introduction
Extraintestinal manifestations of Crohn's disease [CD] have been reported in up to 35% of patients. Between 22% and 44% of patients with extraintestinal manifestations present with mucocutaneous symptoms, which may be categorised as: fissures and fistulas arising through direct extension of the gastrointestinal disease; cutaneous changes secondary to nutritional deficiencies [eg acrodermatitis enteropathica-like syndrome secondary to zinc deficiency]; and cutaneous disorders that have been associated with CD [eg pyoderma gangrenosum, erythema nodosum]. 1 The most common cutaneous manifestations of CD are perianal, peristomal, and perifistular inflammatory lesions.
Parks et al. were the first to describe the presence of sterile, noncaseating, granulomatous lesions of the skin without contact with the gastrointestinal tract in patients with CD. 2 In 1970, this condition was named 'metastatic CD' by Mountain. 3 Those cutaneous manifestations of CD are infrequent and can potentially occur at any location of the body. Genital granulomatosis [GG] is one of them, and it is defined as granulomatous genital inflammation occurring independently from fistulising CD. Hence, a contact with the gastrointestinal tract has to be ruled out. This is sometimes difficult, especially when a simultaneous perianal disease is present. Typical histopathological findings in GG are superficial and deep non-caseating granulomas with giant cells, granulomatous vasculitis, massive oedema of the dermis and a rich eosinophilic infiltration. 4 GG can be encountered as genital swelling or oedema, 'knife-cut' ulcers, fissures, hypertrophic lesions, abscesses or chronic suppuration. These lesions are non-specific and have numerous differential diagnoses including allergic contact dermatitis, angioedema, sexually transmitted diseases [eg herpes simplex, gonorrhea, or Chlamydia infections], sarcoidosis, tuberculosis, Behcet`s disease, foreign body reactions, lymphogranuloma venereum, and many others. Therefore, an interdisciplinary work-up might be necessary in many cases. Since 1965, 123 cases of GG have been reported, mostly in female patients. Recently, a systematic review reporting on 86 cases 5 and a French case series including 22 female patients were published by Laftah et al. 6 However, GG has been described significantly less frequently in male patients and only 37 cases of male GG cases have been published to date, with only one publication including more than one patient, and no comparison between male and female cases has been addressed to date. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In 2014, Mirheydar et al. published a literature review on prepubertal male GG including 17 cases. 8 Beyond clinical presentation, scarce data on treatment efficacy are available, leading to a lack of treatment algorithms in this clinical setting.
The primary aim of this study was to extensively describe GG in patients with CD, with particular attention to male cases. The secondary aim was to provide data on the response to treatments in GG.
Materials and Methods
In this European Crohn's and Colitis Organisation [ECCO] observational multicentre study, cases of GG were retrospectively collected through the CONFER [Collaborative Network For Exceptionally Rare case reports] project. The CONFER project was initiated by ECCO in order to specifically identify and report together rare inflammatory bowel disease [IBD] associations, which otherwise are under-reported due to their exceptional rarity. Once a specific topic is selected by the Steering Committee as a CONFER project, ECCO launches a call to identify similar cases encountered by IBD physicians worldwide. The call to physicians was made through announcements at the ECCO annual congress and in national and international IBD meetings across Europe. Furthermore, the call for similar cases was disseminated by direct emails to all ECCO members and affiliated physicians and on the ECCO website and eNews. Physicians were then prompted to report their cases to the CONFER database using pre-determined standardised Case Reporting Forms [CRF] .
The ECCO CONFER Cases project was centrally approved by the Institutional Research Board [IRB] of the Sheba Medical Center, Israel. All cases included are anonymous, to protect confidentiality and respect patients' privacy. For investigators in need of a local institutional review board [IRB] approval in their own institution to participate in this retrospective project, the project protocol, CRF, and central site IRB approval could be downloaded at the ECCO CONFER website to facilitate this process.
Patients and procedures
CD patients who ever suffered from GG were eligible for inclusion in this project. GG was defined as genital swelling, oedema, ulcer, fissures, hypertrophic lesions, abscesses, or chronic suppuration without contact with gastrointestinal tract Figure 2 The CRF was divided into two sections, one that included patients' and CD characteristics and another that described the details of the GG clinical presentation and treatment outcomes. The phenotype of CD [including age at diagnosis, disease location and behaviour, and perianal involvement] was described using the Montreal classification. 27 Treatment response was assessed retrospectively when reduction in symptoms, healing of fissures and ulcers, or improvement of genital swelling were reported. Primary failure was defined as lack of clinical response and the secondary failure was defined as loss of an initial clinical response.
Statistical analysis
Continuous variables were described as a mean in the case of normal distribution and as a median with range in the case of non-normal distribution. Fisher's exact test was applied to compare the frequencies and the Mann-Whitney test was applied in the case of non-normal distribution for continuous variables. A value of p < 0.05 was considered statistically significant [SPSS version 21.0].
Results
In all, 43 patients [9 males, 34 females] diagnosed with GG were identified from 21 centres. Three cases were excluded because of concomitant rectovaginal or rectolabial fistulas. Only one case of a male patient from the present cohort has been published previously. 8 The presence of granulomas was confirmed histologically in 28 cases [70%]. Histological features are shown in Figure 1 . Gastrointestinal CD was confirmed in all cases either at the time of GG diagnosis, before it, or later. Tuberculosis was ruled out by chest X-ray, IGRA, or tuberculin skin test in all cases.
The main phenotypic characteristics of CD, as well as the time interval between the two diagnoses and the previous exposure to immunosuppressants or anti-tumour necrosis factor [TNF] agents, are described in detail in Table 1 had had some kind of IBD surgery before the occurrence of the GG. There was no significant difference between male and female patients in age at disease onset, localisation, behaviour, prevalence or type of extraintestinal manifestations, and prevalence of perianal manifestations [ Table 2 ].
There were some differences between patients in whom GG was confirmed histologically and patients without histological confirmation. The former patients were significant older at the time of GG diagnosis and also older at the time of Crohn's disease diagnosis. None of the patients without histological confirmation was a smoker or former smoker. Perhaps this is connected to the young age of this group. Anal fistula was present more frequently in patients without histological confirmation. Also, mere colonic as opposed to ileocolonic disease was present more often in patients with histological confirmation of GG. But these differences between both groups were not statistically significant [ Table 3 ].
GG was the first manifestation of CD in 13 patients [30%]. In these patients, GG preceded occurrence of other CD manifestations by a median time of 2 months [range, 0 to 12 months]; seven patients presented with GG within 1 year before IBD diagnosis and six patients developed GG simultaneously with gastrointestinal manifestations. In six patients, GG occurred within the first year after CD diagnosis. In the remaining 21 patients, GG occurred 12 to 422 months after IBD diagnosis. Of note, patients in whom GG was the first IBD manifestation were younger at the time of genital manifestations as opposed to patients in whom GG occurred later [mean age at the time of genital manifestations was 21 years vs 29 years, respectively; p = 0.056]. However, no differences in age at the time of IBD diagnosis were found between both groups [median of 29 years in each group]. Furthermore, all patients with GG as the first disease manifestation were non-smokers, as opposed to eight current smokers and two former smokers in patients with GG occurring later during the course of disease [p = 0.022].
The main characteristics of GG are summarised in After median follow-up period of 30 months [range, 9 to 154 months], clinical response to applied treatment was documented in all but one patient; 26 patients received some kind of monotherapy as first-line treatment attempt. A combination of two or three immunosuppressant drugs was used in 14 patients as first-line therapy. To figure out which was the most potent drug in first-line therapy of GG, we categorisedfive treatment groups from the least to the most potent, as follows: mesalazine [5-ASA; 5-aminosalicylic acid], antibiotics, corticosteroids, immunosuppressant drugs, and anti-TNFs [ Table 4 ]. In cases of combination therapies, we matched the patients to the most potent drug group. One patient had a spontaneous remission and one patient had a surgical remission after vulvoplasty. Only one patient out of three with 5-ASA first-line therapy responded, but had a secondary treatment failure. A monotherapy with antibiotics led to one response out of four cases. However, a treatment response was induced by combining antibiotics [mostly ciprofloxacin or metronidazole] with corticosteroids, immunosuppressants, and/or anti-TNFs in 11 of 13 documented cases. Ten out of 11 patients [91%] responded to initial systemic corticosteroid treatment. Treatment with immunosuppressants [azathioprine, 6-mercaptopurine, or methotrexate] led to response in 10 out of 14 cases. In most cases, azathioprine was used initially in combination with systemic corticosteroids. After stopping corticosteroids, long-term response was achieved in two cases. Eleven patients were treated primarily with anti-TNFs, nine of them achieving response [82%]. Altogether, anti-TNF agents were used in 26 patients during 
Discussion
GG is a rare extraintestinal manifestation of CD. Most publications on that subject are case reports or small case series, the two largest being published very recently. The first of these larger publications was a single-centre retrospective study of 22 female patients with vulvar CD, although intestinal CD was only demonstrated in 14 of them. 6 The second one was a literature review on vulvar CD including 86 patients treated between 1965 and 2013. Both publications focused on female GG and, therefore, did not include male patients. Until now, only 37 male cases had been reported. Mirheydar et al. recently published a case report with literature review describing 17 prepubertal boys with GG. 8 Thus, the present study is the largest original series and it also provides the highest number of adult male GG cases.
GG preceded CD diagnosis in one-third or occurred within the first year of disease in further 20% of our cases. Similar findings had been reported in literature reviews of female GG, with 25% of GG patients without previous intestinal symptoms. 5, 26 Apparently GG tends to occur at an early age, with a median age at diagnosis of GG in our study of 25 years and only one patient being diagnosed with CD when aged over 40 years, in accordance with previous studies. 6, 26 Interestingly, Mirheydar reported that only 29% of prepubertal boys [mean age 10 years] had known CD at the time of GG presentation. In three adolescent boys included in our study, GG preceded CD diagnosis in one, and occurred simultaneously with gastrointestinal symptoms in another one. Of note, perianal disease has been reported in a high proportion of CD patients with GG. In the above-mentioned literature review, 75% of boys with no previous diagnosis of CD had a past history of anal fissures, perianal fistulas or abscesses, anal skin tags, crampy abdominal pain, or rectal bleeding. In our series, 22 patients [55%] had a previous history of perianal disease at the time of GG occurrence. Thus, clinicians should of course be aware of potential GG in young CD patients with unexplained genital swelling, but they should also seek to rule out luminal CD in children or young adults with these symptoms, particularly if there is a past history of perianal fistulas or fissures.
Beyond presentation at an early age [even preceding CD diagnosis] and its association with perianal disease in a high proportion of patients, we found that GG occurs almost exclusively in CD patients with colonic involvement. In our study, colonic involvement of CD [exclusive or together with ileal disease] was present in 97% of the whole cohort and in all those cases with genital symptoms preceding gastrointestinal manifestations. Laftah et al., in a smaller series of 14 female patients with vulvar CD, reported 72% colonic involvement. 6 Regarding luminal CD phenotype, it is noteworthy that 70% had an inflammatory disease behaviour and only five patients had a history Finally, from our results it could be concluded that GG development is not necessarily associated with luminal disease activity, as 30% of patients were in clinical or endoscopic/radiological remission. This is comparable to the study of Karmiris et al., who found an association between active IBD and presence of EIM in 61.1% of the patients. 30 No large series of male GG are available and, to date, only one literature review focused on male GG has been published. Mirheydar et al. recently reviewed a total of 17 paediatric [prepubertal] male cases of genital CD. 8 As in our nine male cases, most of them had penile and scrotal disease, and only a minority had foreskin involvement. Contrary to what it might be thought from that review, none of our male cases had a prepubertal onset of GG, and only one-third presented during adolescence. Although we specifically assessed if there were phenotypic differences in CD between male and female cases, we did not find any.
To date, the natural history of GG has not been well documented; apparently the course of disease ranges from spontaneous healing 31 to lesions refractory to medical therapy, requiring surgery. [32] [33] [34] [35] The present retrospective study also focused on treatment results. A prompt response to conventional CD treatment was observed in most cases. The treatment choice was mostly affected by gastrointestinal symptoms. However, a very good response rate to systemic corticosteroids of up to 91% could be observed. Antibiotics, especially ciprofloxacin and metronidazole, were also effective in 85%, but mostly in combination with corticosteroids or immunosuppressants. On the other hand, we documented clinical response to antibiotic monotherapy in only 25% of the cases. For metronidazole, there seems to be some evidence of clinical efficacy in acute flares due to secondary infection causing cellulitis and abscess formation, but with no effect on the genital oedema. Also, there is no evidence that GG symptoms could be improved by antibiotics in the long term. 6, 8 Therefore, the combination of corticosteroids, azathioprine, and metronidazole could be an effective first-line therapy, especially in cases of secondary infections. We also found a high response rate to anti-TNF therapy, with only 15% of primary failures. In fact, response to anti-TNFs has also been reported after failure of antibiotics, corticosteroids, or immunosuppressants in some cases. 5 As in previous large series, the main limitations of the present study come from its retrospective design. This led to histological corroboration of only 70% of cases. The presence of subacute or chronic inflammatory infiltrate, epidermal ulceration, together with non-caseating tuberculoid granulomas, strongly supports the diagnosis and therefore some authors pose that biopsy samples for histological study are mandatory. 5 But these histological features do not confirm GG because, for example, sarcoidosis or foreign body reactions might have the same histological presentation. On the other hand, in the recently published study of Laftah, histological features of CD were found in only 69% of the biopsies of the vulva and non-caseating granulomas were found in 89% of these cases. 6 All of our cases had histologically confirmed gastrointestinal CD and typical clinical presentation of GG. Comparing the cases with [28] and without [12] histological confirmation of genital manifestation, the main difference in both groups was the age at onset of GG. The group without histological confirmation was younger at diagnosis of GG. Perhaps this is the reason why biopsies were taken less. No significant difference was seen in phenotype of CD or treatment outcome. However, our series excluded those patients with concomitant active perianal disease, as well as those in whom gastrointestinal CD involvement was never demonstrated. The study design also made it difficult to evaluate the best therapeutic approach to these patients, as there was not a preestablished treatment algorithm or a standardised way to measure response.
In conclusion, GG is a rare extraintestinal manifestation of CD that occurs predominantly in young females with colonic involvement and perianal disease. In almost half of the patients, GG precedes or develops early after CD diagnosis. Systemic corticosteroids in combination with azathioprine or, in case of concomitant infection with metronidazole, could be recommended as a first-line treatment, although anti-TNF agents seem also to be an effective treatment option in most cases.
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